Dupilumab versus Cyclosporine for Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.

Dupilumab versus Cyclosporine for Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index. Acta Derm Venereol. 2019 May 17;: Authors: Ariëns LFM, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bégo-Le Bagousse G, Lu Y, Rizova E, Graham NMH, Pirozzi G, De Bruin-Weller M, Eckert L Abstract Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD), and cyclosporine for severe AD for ≤ 1 year. The efficacy of these treatments was compared indirectly. Regression models used pooled patient-level data to estimate response (Eczema Area and Severity Index (EASI) EASI-50/EASI-75 at weeks 12-16 and 24-30) to dupilumab 300 mg every 2 weeks (weeks; CHRONOS [NCT02260986]) or cyclosporine (University Medical Center). Models were adjusted for sex, baseline EASI, and thymus and activation-regulated chemokine level. A total of 106 patients received dupilumab (+topical corticosteroids; +TCS), and 57 received cyclosporine (+TCS). Among University Medical Center patients, estimated EASI-50 responders were, dupilumab vs. cyclosporine, 91% vs. 77% (p = 0.038; weeks 12-16), and 96% vs. 67% (p 
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research

Related Links:

CONCLUSIONS: In adolescents with moderate-to-severe AD, dupilumab's pharmacokinetic profile was similar to that in adults. These 52-week safety and efficacy data support long-term use of dupilumab in this patient population. What's already known about this topic? Adolescents with moderate-to-severe atopic dermatitis (AD) have high unmet medical need, with significant disease burden and limited treatment options. Dupilumab (monoclonal antibody against interleukin-4 receptor α) is approved for the treatment of adolescents with moderate-to-severe AD who are inadequately responsive to standard of care (U.S.A.) or candida...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Conditions:   Atopic Dermatitis;   Atopic Eczema Interventions:   Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo;   Drug: Protopic, tacrolimus ointment 0.1% Sponsors:   Jacob Thyssen;   LEO Pharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractBackgroundPatients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma.ObjectiveThe aim was to determine the impact of dupilumab on infection rates in patients w...
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research
In conclusion, MP is not specific for benignity, even when multiple simultaneous lesions are affected. Inflammatory changes can make melanocytic lesions difficult to interpret, both on dermoscopic regression features and on histopathologic examination. Therefore, it is recommended to consider the complete excision of melanocytic lesions with atypical vessels and/or extensive regression phenomena more than 50%. Further studies are needed to know whether the presence of a melanoma could induce a remote immune response in other benign melanocytic lesions.
Source: Melanoma Research - Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research
Conclusion Parents ’ perceptions about topical corticosteroids might negatively influence treatment outcomes. Pharmacy staff has an important role to inform parents of children with eczema on the appropriate use of topical corticosteroids and emollients. Counseling should not be influenced by their own prejudices ab out topical corticosteroids. Close collaboration between primary care providers should ensure that parents receive uniform messages.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
Itch is the most bothersome symptom of atopic dermatitis (AD). Improvement in itch is an important marker of treatment benefit in AD patients. In dupilumab (DPL) phase 3, double-blind, placebo (PBO)-controlled trials, we assessed intensity and frequency of itch using Peak Pruritus Numerical Rating Scale (PP-NRS), Scoring AD (SCORAD) itch Visual Analog Scale (VAS), and Patient-Oriented Eczema Measure (POEM) itch item, in adults with moderate-to-severe AD who received DPL 300mg every 2 weeks (q2w) or PBO monotherapy (pooled SOLO 1&2: NCT02277743, NCT02277769; 16-week [Wk]), or combined with topical corticosteroids (CHRONOS: ...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Interventional Studies, Clinical and Patient Outcomes Research Source Type: research
This study was supported by grants from GSK and the UK Medical Research Council (U105178805). Conflict of Interest Statement AM has grant funding from GSK and AstraZeneca/MedImmune. MB, DJ, AP, DT, and AvO are employees of GSK. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We are grateful to the Ares staff, genotyping facility, and flow cytometry core for their technical assistance. We thank Jen Walker for advice on the manuscript. Supplementary Material The Supplem...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Corticosteroid Therapy | Dermatitis | Dermatology | Eczema | Restasis